Cargando…
Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of...
Autores principales: | Yoshimi, Ryusuke, Ishigatsubo, Yoshiaki, Ozato, Keiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373075/ https://www.ncbi.nlm.nih.gov/pubmed/22701487 http://dx.doi.org/10.1155/2012/718237 |
Ejemplares similares
-
Clinical and Pathological Roles of Ro/SSA Autoantibody System
por: Yoshimi, Ryusuke, et al.
Publicado: (2012) -
Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus
por: Gomez-Bañuelos, Eduardo, et al.
Publicado: (2022) -
Common and Specific Associations of Anti-SSA/Ro60 and Anti-Ro52/TRIM21 Antibodies in Systemic Lupus Erythematosus
por: Menéndez, Aurora, et al.
Publicado: (2013) -
Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23–Th17 pathway
por: Espinosa, Alexander, et al.
Publicado: (2009) -
The interconnected roles of TRIM21/Ro52 in systemic lupus erythematosus, primary Sjögren’s syndrome, cancers, and cancer metabolism
por: Hsu, Chueh-Hsuan, et al.
Publicado: (2023)